Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 711

1.

Immunogenicity of Golimumab and its Clinical Relevance in Patients With Ulcerative Colitis.

Adedokun OJ, Gunn GR 3rd, Leu JH, Gargano C, Xu Z, Sandborn WJ, Rutgeerts P, Shankar G.

Inflamm Bowel Dis. 2019 Feb 8. doi: 10.1093/ibd/izz003. [Epub ahead of print]

PMID:
30753466
2.

Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies.

Panaccione R, Löfberg R, Rutgeerts P, Sandborn WJ, Schreiber S, Berg S, Maa JF, Petersson J, Robinson AM, Colombel JF.

J Crohns Colitis. 2019 Feb 9. doi: 10.1093/ecco-jcc/jjy223. [Epub ahead of print]

PMID:
30753371
3.

Gene and Mirna Regulatory Networks During Different Stages of Crohn's Disease.

Verstockt S, De Hertogh G, Van der Goten J, Verstockt B, Vancamelbeke M, Machiels K, Van Lommel L, Schuit F, Van Assche G, Rutgeerts P, Ferrante M, Vermeire S, Arijs I, Cleynen I.

J Crohns Colitis. 2019 Jan 18. doi: 10.1093/ecco-jcc/jjz007. [Epub ahead of print]

PMID:
30657881
4.

Difference in Pathomechanism Between Crohn's Disease and Ulcerative Colitis Revealed by Colon Transcriptome.

Yang L, Tang S, Baker SS, Arijs I, Liu W, Alkhouri R, Lan P, Baker RD, Tang Z, Ji G, Rutgeerts P, Vermeire S, Zhu R, Zhu L.

Inflamm Bowel Dis. 2018 Dec 4. doi: 10.1093/ibd/izy359. [Epub ahead of print]

PMID:
30517639
5.

No Change in Determining Crohn's Disease Recurrence or Need for Endoscopic or Surgical Intervention With Modification of the Rutgeerts Scoring System.

Rivière P, Vermeire S, Irles-Depe M, van Assche G, Rutgeerts P, de Buck van Overstraeten A, Denost Q, Wolthuis A, D'Hoore A, Laharie D, Ferrante M.

Clin Gastroenterol Hepatol. 2018 Oct 4. pii: S1542-3565(18)31079-6. doi: 10.1016/j.cgh.2018.09.047. [Epub ahead of print]

PMID:
30291910
6.

Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis.

Colombel JF, Adedokun OJ, Gasink C, Gao LL, Cornillie FJ, D'Haens GR, Rutgeerts PJ, Reinisch W, Sandborn WJ, Hanauer SB.

Clin Gastroenterol Hepatol. 2018 Sep 26. pii: S1542-3565(18)31024-3. doi: 10.1016/j.cgh.2018.09.033. [Epub ahead of print]

7.

Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab.

Reinisch W, Colombel JF, Gibson PR, Rutgeerts P, Sandborn WJ, Tarabar D, Huyck S, Khalifa A, Marano C, Philip G, Yao R, Zhang H, Cornillie F.

Inflamm Bowel Dis. 2019 Jan 1;25(1):163-171. doi: 10.1093/ibd/izy229.

PMID:
29982631
8.

Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis.

Telesco SE, Brodmerkel C, Zhang H, Kim LL, Johanns J, Mazumder A, Li K, Baribaud F, Curran M, Strauss R, Paxson B, Plevy S, Davison T, Knight L, Dibben S, Schreiber S, Sandborn W, Rutgeerts P, Siegel CA, Reinisch W, Greenbaum LE.

Gastroenterology. 2018 Oct;155(4):1008-1011.e8. doi: 10.1053/j.gastro.2018.06.077. Epub 2018 Jul 4.

9.

Long-term Benefit of Golimumab for Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension.

Reinisch W, Gibson PR, Sandborn WJ, Feagan BG, Strauss R, Johanns J, Padgett L, Adedokun OJ, Colombel JF, Collins J, Rutgeerts P, Tarabar D, Marano C.

J Crohns Colitis. 2018 Jun 18. doi: 10.1093/ecco-jcc/jjy079. [Epub ahead of print]

PMID:
29917070
10.

Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.

Rutgeerts P, Gasink C, Chan D, Lang Y, Pollack P, Colombel JF, Wolf DC, Jacobstein D, Johanns J, Szapary P, Adedokun OJ, Feagan BG, Sandborn WJ.

Gastroenterology. 2018 Oct;155(4):1045-1058. doi: 10.1053/j.gastro.2018.06.035. Epub 2018 Aug 29.

PMID:
29909019
11.

Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.

Sandborn WJ, Rutgeerts P, Gasink C, Jacobstein D, Zou B, Johanns J, Sands BE, Hanauer SB, Targan S, Ghosh S, de Villiers WJS, Colombel JF, Feagan BG.

Aliment Pharmacol Ther. 2018 Jul;48(1):65-77. doi: 10.1111/apt.14794. Epub 2018 May 24.

12.

Performance of Crohn's disease Clinical Trial Endpoints based upon Different Cutoffs for Patient Reported Outcomes or Endoscopic Activity: Analysis of EXTEND Data.

Feagan B, Sandborn WJ, Rutgeerts P, Levesque BG, Khanna R, Huang B, Zhou Q, Maa JF, Wallace K, Lacerda A, Thakkar RB, Robinson AM.

Inflamm Bowel Dis. 2018 Apr 23;24(5):932-942. doi: 10.1093/ibd/izx082.

PMID:
29668919
13.

Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-Based vs Trough Concentration-Based Dosing of Infliximab.

Pouillon L, Ferrante M, Van Assche G, Rutgeerts P, Noman M, Sabino J, Vande Casteele N, Gils A, Vermeire S.

Clin Gastroenterol Hepatol. 2018 Aug;16(8):1276-1283.e1. doi: 10.1016/j.cgh.2017.11.046. Epub 2017 Dec 1.

PMID:
29203225
14.

Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis.

Colombel JF, Sandborn WJ, Reinisch W, Peyrin-Biroulet L, Panaccione R, Rutgeerts P, Hanauer SB, Ghosh S, Van Assche G, Robinson AM, Lau W, Maa JF, Huang B, Pappalardo B, Read H.

Aliment Pharmacol Ther. 2018 Jan;47(2):219-228. doi: 10.1111/apt.14420. Epub 2017 Nov 21.

PMID:
29159817
15.

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.

Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Vaňásek T, Danalioglu A, Novacek G, Armuzzi A, Hébuterne X, Travis S, Danese S, Reinisch W, Sandborn WJ, Rutgeerts P, Hommes D, Schreiber S, Neimark E, Huang B, Zhou Q, Mendez P, Petersson J, Wallace K, Robinson AM, Thakkar RB, D'Haens G.

Lancet. 2018 Dec 23;390(10114):2779-2789. doi: 10.1016/S0140-6736(17)32641-7. Epub 2017 Oct 31. Erratum in: Lancet. 2018 Dec 23;390(10114):2768.

PMID:
29096949
16.

Genetic and Transcriptomic Bases of Intestinal Epithelial Barrier Dysfunction in Inflammatory Bowel Disease.

Vancamelbeke M, Vanuytsel T, Farré R, Verstockt S, Ferrante M, Van Assche G, Rutgeerts P, Schuit F, Vermeire S, Arijs I, Cleynen I.

Inflamm Bowel Dis. 2017 Oct;23(10):1718-1729. doi: 10.1097/MIB.0000000000001246.

PMID:
28885228
17.

Chromoendoscopy versus narrow band imaging in UC: a prospective randomised controlled trial.

Bisschops R, Bessissow T, Joseph JA, Baert F, Ferrante M, Ballet V, Willekens H, Demedts I, Geboes K, De Hertogh G, Vermeire S, Rutgeerts P, Van Assche G.

Gut. 2018 Jun;67(6):1087-1094. doi: 10.1136/gutjnl-2016-313213. Epub 2017 Jul 11.

PMID:
28698230
18.

Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis.

D'Haens GR, Sandborn WJ, Zou G, Stitt LW, Rutgeerts PJ, Gilgen D, Jairath V, Hindryckx P, Shackelton LM, Vandervoort MK, Parker CE, Muller C, Pai RK, Levchenko O, Marakhouski Y, Horynski M, Mikhailova E, Kharchenko N, Pimanov S, Feagan BG.

Aliment Pharmacol Ther. 2017 Aug;46(3):292-302. doi: 10.1111/apt.14164. Epub 2017 Jun 1.

19.

Corrigendum: Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease.

Khanna R, Zou G, Stitt L, Feagan BG, Sandborn WJ, Rutgeerts P, McDonald JWD, Dubcenco E, Fogel R, Panaccione R, Jairath V, Nelson S, Shackelton LM, Huang B, Zhou Q, Robinson AM, Levesque BG, D'Haens G.

Am J Gastroenterol. 2017 Jun;112(6):975. doi: 10.1038/ajg.2017.120. Epub 2017 Apr 18. No abstract available.

PMID:
28417993
20.

Vedolizumab Induces Long-term Mucosal Healing in Patients With Crohn's Disease and Ulcerative Colitis.

Noman M, Ferrante M, Bisschops R, De Hertogh G, Van den Broeck K, Rans K, Rutgeerts P, Vermeire S, Van Assche G.

J Crohns Colitis. 2017 Sep 1;11(9):1085-1089. doi: 10.1093/ecco-jcc/jjx048.

PMID:
28369329

Supplemental Content

Loading ...
Support Center